Cite
Cai L, Qiu X, Yang H, et al. Evaluation on efficacy and safety of the addition of X-knife therapy to gefitinib in NSCLC patients with symptomatic brain metastases. Oncotarget. 2016;8(34):57470-57476doi: 10.18632/oncotarget.10420.
Cai, L., Qiu, X., Yang, H., Lai, M., Shan, C., Hong, W., Li, J., Luo, L., Zhang, P., & Wang, L. (2017). Evaluation on efficacy and safety of the addition of X-knife therapy to gefitinib in NSCLC patients with symptomatic brain metastases. Oncotarget, 8(34), 57470-57476. https://doi.org/10.18632/oncotarget.10420
Cai, Linbo, et al. "Evaluation on efficacy and safety of the addition of X-knife therapy to gefitinib in NSCLC patients with symptomatic brain metastases." Oncotarget vol. 8,34 (2017): 57470-57476. doi: https://doi.org/10.18632/oncotarget.10420
Cai L, Qiu X, Yang H, Lai M, Shan C, Hong W, Li J, Luo L, Zhang P, Wang L. Evaluation on efficacy and safety of the addition of X-knife therapy to gefitinib in NSCLC patients with symptomatic brain metastases. Oncotarget. 2016 Jul 06;8(34):57470-57476. doi: 10.18632/oncotarget.10420. eCollection 2017 Aug 22. PMID: 28915686; PMCID: PMC5593658.
Copy
Download .nbib